Translational Relevance 26
BIIB028 is a novel prodrug designed to be dephosphorylated to an active metabolite that inhibits 27 the activity of heat shock protein 90 (Hsp90) through binding to a conserved pocket in the N-28
terminal ATP-binding domain of Hsp90. Hsp90 is a ubiquitous molecular chaperone protein 29 involved in folding, activation, and assembly of many proteins, including key mediators of signal 30 transduction, cell cycle control, and transcriptional regulation. This first-in-human phase I study 31 established the maximum tolerated dose at 144 mg/m 2 IV twice a week and confirmed that 32 BIIB028 is well tolerated, with pharmacokinetic-pharmacodynamic data supporting proof-of-33 mechanism with clinically relevant antitumor activity. Substantial increase in Hsp70 and 34 decrease in HER-2 extracellular domain in peripheral blood mononuclear cells and serum were 35
observed with BIIB028. Prolonged stable disease by Response Evaluation Criteria in Solid 36
Tumors suggests that BIIB028 is an active anticancer agent and its combination with other 37 molecules will be of great clinical interest. 38
. The maximum tolerated dose 50 was 144 mg/m 2 . Dose-limiting toxicities were syncope (n=1) and fatigue (n=1). Common 51 toxicities at least possibly related to drug were grade 1-2, including fatigue (46%), diarrhea 52 (44%), nausea (44%), vomiting (29%), hot flushes (29%) and abnormal dreams (17%). The 53 concentration-time curves for Day 1 and Day 18 for both prodrug and active metabolite 54 (CF2772) showed a negligible difference. There was a dose-dependent increase in plasma 55 exposure for BIIB028 (CF3647) and CF2772 with plasma half-life of 0.5 and 2.1 hours, 56 respectively. Pharmacodynamic analyses demonstrated significant increases in Hsp70 in 57 peripheral blood mononuclear cells and significantly decreased circulating human epidermal 58 growth factor receptor 2-extracellular domain in all patients who received BIIB028 at dose 59 levels ≥48mg/m 2
INTRODUCTION 64 65
Heat shock protein 90 (Hsp90) is a ubiquitous molecular chaperone protein involved in folding, 66 activation, and assembly of many proteins, including key mediators of signal transduction, cell 67 cycle control, and transcriptional regulation (1, 2). Hsp90 client proteins include transmembrane 68 tyrosine kinases (HER-2/neu, EGFR, MET, IGF-1R), metastable signaling proteins (AKT, Raf-1, 69 IKK), mutated signaling proteins (p53, Kit, Flt3, , chimeric signaling proteins (NPM-ALK, 70
Bcr-Abl), steroid receptors (androgen, estrogen, and progesterone receptors), and cell cycle 71 regulators (cdk4, cdk6) (1-4). 72 BIIB028 (CF3647) is a prodrug designed to be dephosphorylated in vivo to an active metabolite, 73 CF2772, which inhibits the activity of Hsp90. CF2772 binds to a conserved binding pocket in the CTCAE, Version 3.0). All male and female patients of childbearing potential were educated 110 about practicing effective contraception during the study and were willing and able to continue 111 contraception for 3 months after their last dose of study treatment. All patients signed an 112 informed consent and the protocol was approved by the IRB at each of the treating institutions. 113
Trial Design 114
Using a standard 3+3 dose-escalation design, BIIB028 was administered intravenously (IV; 30-115 minute infusion from 6 mg/m 2 to196mg/m 2 ) twice weekly. An amendment increased infusion to 1 116 hour at the 144mg/m 2 dose for better tolerance. The starting dose was based on the Good 117 Laboratory Practice (GLP) preclinical toxicology studies performed in rats and dogs using the 118 same dosing schedule (twice weekly). The severely toxic dose in 10% of animals (STD10) was 119 determined to be 10 mg/kg, or 60 mg/m 2 . Therefore, using this value as the basis for calculation 120 of 1/10th STD10 in the more sensitive species, the supported starting clinical dose was 121 determined to be 6 mg/m 
Definition of DLT 126
DLT was assessed during Cycle 1 (first 21 days) and was defined as any study treatment 127 adverse event (AE) that met prespecified criteria. Any toxicity ≥grade 3 according to NCI 128 CTCAE Version 3.0 met the DLT criteria with the following exceptions: Nausea/vomiting and 129 diarrhea were considered DLTs only if they reached ≥grade 3 for 3 days despite supportive 130 care, asymptomatic Grade 3 AST, ALT, lipase, or amylase ≤ 7 days, alopecia, grade 3, fatigue ≤ 131 7 days and Grade ≥ 3 thrombocytopenia or Grade ≥ 3 neutropenia lasting ≤ 7 days. 132
Alternatively, febrile neutropenia of any duration was considered a DLT. If one dose in Cycle 1 133 was missed for non-toxicity reasons, the DLT assessment period for this subject was extended 134 to evaluate 6 completed doses. If 2 doses were missed in Cycle 1 for non-toxicity reasons, an 135 additional patient was added to that cohort to enable DLT assessment. Missed doses related to 136 toxicity were not replaced. 137 The following analyses were performed: standard safety assessments according to NCI-145 
Follow-Up Assessment 138

Pharmacokinetics (PK)/Pharmacodynamics (PD) 151
Serial blood samples were collected for PK/PD evaluation on Days 1 and 18 during and after 152 the infusion of the prodrug at the following time points for Cohorts 1-6: pre-dose, 0.083, 0.25, 153 0.5, 0.75, 1, 1.5, 2.5, 4.5, 8.5, and 24 hours after the start of the infusion. For Cohort 7, which 154 had the extended infusion time of 1 hour, blood samples were taken at: pre-dose, 0.083, 0.25, 155 0.5, 1.0, 1.25, 1.5, 2, 3, 5, and 9 hours after the start of the infusion. Plasma concentrations of 156 CF3647 (BIIB028) and CF2772 (active metabolite) at each time point were quantified via mass 157 spectrometry. The PK of both analytes was evaluated by non-compartmental analysis (NCA) 158 using WinNonlin Phoenix version 6.1 software. 159
The biomarker assays, namely, HER-2 ECD and Hsp70, were performed as previously 160 described 12 . Briefly, the serum HER-2 assay was carried out using the Serum HER-2/neu IVD 161
Test from Siemens Healthcare Diagnostics, USA. For the Hsp70 assay, peripheral blood was 162 drawn into 8 mL vacutainer cell preparation tubes (BD, Franklin, NJ #362753) and PBMC were 163 separated per manufacturer's instructions. The assay was performed using the Total Hsp70 164
Whole Cell Lysate Kits on an electrochemiluminescence platform (Cat. no. K111EVD-3, Meso 165
Scale Discovery, Gaithersburg, MD, USA). Total protein concentrations in PBMC lysates were 166 normalized using a BCA assay in accordance with internally validated standard operating 167 procedures based on instructions from the BCA Protein Assay Kit (Pierce, Rockford, IL # 168
Research. Thirty-one patients discontinued study treatment due to disease progression, six patients due to 180
AEs and four patients due to withdrawal of consent. 181
Dose Escalation 182
Two drug-related DLTs were observed in two patients (out of 5) treated in the dose cohort of 183 192 mg/m 2 administered twice weekly using a 30-minute IV infusion. The two DLTs included 184 grade 3 syncope that occurred approximately 12 hours after the third dose of BIIB028 and grade 185 3 fatigue that occurred 4 days after the second dose of BIIB028. Both DLTs resolved without 186 sequelae after BIIB028 discontinuation. Therefore, the protocol was amended and subsequent 187 subjects received study drug of 144 mg/m 2 twice weekly at an increased infusion time from 30 188 minutes to 60 minutes potentially to enhance tolerability of the dose. Subjects enrolled before 189 the amendment continued with their dosing schedule delivered via 30-minute infusions. 190
Tolerability 191
All patients (100%) reported at least one adverse event. Of note, common toxicities potentially 192 related to treatment were fatigue (46%), diarrhea (44%), nausea (44%), hot flashes (29%) and 193 vomiting (29%). These were generally mild and are summarized in Table 2 . In addition, 194 abnormal vivid dreams, dizziness and headache were seen in 7 (17%), 9 (22%) and 5 (12%) 195 patients, respectively. There was only one grade 4 event, which was hypercalcemia (not related 196
Research. 19, 2013; DOI: 10.1158 /1078 to BIIB028) and no grade 5 events were reported. There were two deaths, but these were 197 considered unrelated to BIIB028 (1 death due to acute renal failure and multi-organ failure and 198 the other due to septic shock). There was no significant QTc prolongation seen on ECGs. There 199 were 13 other severe adverse events (SAEs) reported in 9 patients. Only 2 of the 13 SAEs were 200 reported as related to BIIB028; grade 2 confusion in a patient enrolled in the dose cohort level of 201 144 mg/m 2 was considered serious and it resolved spontaneously. The 2 nd related SAE was 202 following each dose of BIIB028 were approximately 1500-2000 ng*hr/mL and 5-10 µg/mL, 225 respectively, and the terminal half-life was about 1 hour. In the current clinical study, the 226 average CF2772 AUC0-inf for the 96 mg/m 2 dose cohort was approximately 2600 ng*h/mL, with 227 a Cmax around 1.8 µg /mL. At the highest clinical dose level, 192 mg/m 2 BIIB028, the average 228 AUC0-inf and Cmax of CF2772 were approximately 5100 ng*h/mL and 3.3 µg /mL, respectively. 229
The mean half-life of CF2772 in both cohorts was about 2 hours. This phase I clinical trial evaluated BIIB028, a prodrug and its active metabolite CF2772, a 258 selective Hsp90 inhibitor. Preclinical studies showed that target organs (gastrointestinal 259 including gall bladder, bone marrow, adrenals, and testes) could be severely affected in relation 260 to dose response. The relevant target organs are clinically monitorable; therefore, the starting 261 dose and the escalation proposal in addition to safety monitoring were based on a balance of 262 minimizing the exposure of patients to an ineffective dose while ensuring participant safety. 263 BIIB028 was initially administered twice weekly as a 30-minute infusion in 21-day cycles, but 264 later, given that the one syncopal event occurred shortly after the infusion; this might represent 265 a Cmax-driven effect. Preclinical studies were also suggestive of Cmax-related toxicity. 266
Consequently, the protocol was amended to increase the infusion duration to 60 minutes for the 267 144mg/m 2 dose, which reduced Cmax, was well tolerated and established the MTD of the study. 268 BIIB028 was well tolerated with grade 1-2 gastrointestinal events, fatigue and hot flashes being 269 the most common toxicities related to treatment. Interestingly, there was no significant liver 270 toxicity seen, as had been expected from preclinical studies on BIIB028 and from previous 271 experiences with other Hsp90 inhibitors (17, 18) . In fact, the absence of liver toxicity represents 272 a significant benefit of BIIB028 since this toxicity was previously reported as a major side effect 273 of IPI-504 in a phase III trial of progressive gastrointestinal stromal tumor (GIST) (ASCO, 2010 274
Gastrointestinal Cancer Symposium, Abstract # 64). 275
Alternatively, patients had abnormally vivid dreams as a distinctive psychiatric adverse event in 276 addition to symptoms related to central nervous system dysfunction such as dizziness, 277 confusion, tremor and headache. On the other hand, no ocular toxicity was seen in our study in 278 contradiction to other Hsp90 inhibitor studies (19). There is no clear explanation for these neuro- The PD studies clearly showed an anticipated strong correlation between active drug levels 294 (CF2772) and an increase of Hsp70 and decrease of HER-2 levels. Hsp70 is a well-295 documented surrogate marker of Hsp90 inhibition that may offer cells another mode for survival 296 and this may partly explain the absence of a CR/PR response within the study group (21, 22) . 297
Hsp70 is often increased in response to treatment with Hsp90 inhibitors as a biomarker for 298 successful Hsp90 inhibition (19, 21, 22) . . How Hsp70 levels can be used to predict response to 299
Hsp90 inhibitors or used to select patients likely to benefit from this class of drugs has not yet 300 been established and a larger or different study is needed to evaluate this possibility. Similarly, 301 the change in the serum HER-2 level observed in a mixed group of solid tumor patients might 302
indicate the potential utility of BIIB028 in a wide range of tumor types, especially HER-2 positive 303 tumors. Overall, the observed biomarker changes provide a strong proof of pathway interdiction 304
Research. 
